Article Text
Abstract
This piece introduces the JME symposium ‘The benefit/risk ratio challenge in clinical research, and the case of HIV cure.’
- HIV Infection and AIDS
- Research Ethics
- Ethics
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Statistics from Altmetric.com
Footnotes
Funding This work was funded by NIAID grants 1 R01 AI114617-01A1 and 1 R56 AI114617-01, both titled ‘HIV cure studies: risk, risk perception, and ethics’.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.
Linked Articles
- Benefits to nonparticipants
Other content recommended for you
- How to keep high-risk studies ethical: classifying candidate solutions
- The social value of candidate HIV cures: actualism versus possibilism
- When to start paediatric testing of the adult HIV cure research agenda?
- Why cure, why now?
- First-in-human HIV-remission studies: reducing and justifying risk
- Cure research and consent: the Mississippi Baby, Barney Clark, Baby Fae and Martin Delaney
- Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis
- Haemopoietic stem cell transplantation for genetic disorders
- Sickle cell disease: a neglected chronic disease of increasing global health importance
- Are the risks of treatment to cure a child with severe sickle cell disease too high?